FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to immunology and biotechnology. There are offered versions of a TNF-alpha polypeptide wherein a number of heavy-chain single domain antibodies is equal to two. What is described is coding nucleic acid. There are disclosed versions of the compositions, a polypeptide-based kit, as well as versions of using it. What is described is a method for producing the polypeptide with using nucleic acid.
EFFECT: use of the invention provides the substantial growth of cytotoxicity lC50 (of the order of 10-9) that can find further application in therapy of TNFα-mediated disorders.
52 cl, 18 dwg, 11 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED NANOBODIES AGAINST TUMOUR NECROSIS FACTOR-ALPHA | 2006 |
|
RU2464276C2 |
| SINGLE-DOMAIN ANTIBODIES DIRECTED AGAINST TUMOUR NECROSIS FACTOR ALPHA, AND USE THEREOF | 2012 |
|
RU2704232C2 |
| PROTEINS BINDING PROSTAGLANDIN E2 AND USING THEM | 2009 |
|
RU2559525C2 |
| METHODS AND COMPOSITIONS FOR AUTOIMMUNE AND INFLAMMATORY DISEASES TREATMENT | 2012 |
|
RU2639540C2 |
| GLA DOMAINS AS THERAPEUTIC AGENTS | 2014 |
|
RU2705786C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT OF IMMUNE DISEASES | 2005 |
|
RU2342950C2 |
| ANTI-IL-17 ANTIBODIES, METHODS OF THEIR PRODUCTION AND APPLICATION | 2014 |
|
RU2577228C2 |
| COMPOSITION BASED UPON THE PROTEINS OF ENAMEL MATRIX FOR MODULATING IMMUNE RESPONSE | 2002 |
|
RU2295972C2 |
| QUINOLINE DERIVATIVES FOR USE IN TREATING INFLAMMATORY DISEASES | 2019 |
|
RU2827865C2 |
| OBTAINING HETEROMULTIMERIC PROTEINS USING MAMMALIAN CELLS | 2015 |
|
RU2727012C2 |
